D-Dimer Values and Venous Thromboembolism in Patients With COVID-19 in Japan
— From the CLOT-COVID Study —

Nobutaka Ikeda, MD; Sen Yachi, MD; Makoto Takeyama, MD; Yuji Nishimoto, MD; Ichizo Tsujino, MD; Junichi Nakamura, MD; Naoto Yamamoto, MD; Hiroko Nakata, MD; Satoshi Ikeda, MD; Michihisa Umetsu, MD; Shizu Aikawa, MD; Hiroya Hayashi, MD; Hirono Satokawa, MD; Yoshinori Okuno, MD; Eriko Iwata, MD; Yoshito Oghara, MD; Akane Kondo, MD; Takehisa Iwai, MD; Norikazu Yamada, MD; Tomohiro Ogawa, MD; Takao Kobayashi, MD; Makoto Mo, MD; Yugo Yamashita, MD for the CLOT-COVID Study Investigators

Background: To date, there are no large-scale data on the association between D-dimer levels at admission and the occurrence of venous thromboembolism (VTE) in Japanese patients with coronavirus disease 2019 (COVID-19).

Methods and Results: The CLOT-COVID study was a retrospective, multicenter cohort study enrolling consecutive hospitalized patients with COVID-19 across 16 centers in Japan from April 2021 to September 2021. Among 2,894 enrolled patients, 2,771 (96%) had D-dimer levels measured at admission. Patients were divided into 3 groups based on tertiles of D-dimer levels at admission (1st tertile, D-dimer ≤0.5 μg/mL, n=949; 2nd tertile, D-dimer 0.51–1.09 μg/mL, n=894; 3rd tertile, D-dimer ≥1.1 μg/mL, n=928). The higher the tertile group, the more severe the COVID-19 status at admission. The incidence of VTE during hospitalization was highest in the 3rd tertile group (1st tertile, 0.3%; 2nd tertile, 0.3%; 3rd tertile, 3.6%; P<0.001). Even after adjusting for confounders in the multivariable logistic regression model, the higher D-dimer levels in the 3rd tertile (≥1.1 μg/mL) were independently associated with a higher risk of VTE during hospitalization (adjusted odds ratio 4.83 [95% confidence interval 1.93–12.11; P<0.001]; reference=1st tertile).

Conclusions: Higher D-dimer levels at admission were associated with a higher risk of VTE events during hospitalization in Japanese patients with COVID-19. This could be helpful in determining patient-specific anticoagulation management strategies for COVID-19 in Japan.

Key Words: COVID-19; D-dimer; Venous thromboembolism

The association between coronavirus disease 2019 (COVID-19) infection and arterial and venous thrombosis, including venous thromboembolism (VTE), has been reported worldwide. In Western countries, anticoagulation therapy has been recommended for all hospitalized COVID-19 patients due to the high risk of thrombosis and the potential benefit for improvement of the survival rate by the primary prevention of thrombosis, but this remains controversial, especially with regard to the optimal intensity of anticoagulation therapy. In contrast, previous studies have suggested that the risk of thrombosis in Japanese patients with COVID-19 may be relatively
low, and racial differences may have to be considered when deciding anticoagulation management strategies.12,13

The International Society of Thrombosis and Haemostasis (ISTH) interim guidance on the recognition and management of coagulopathy in COVID-19 recommends measuring coagulation markers in all patients with COVID-19.14 D-Dimer, thought to be one of the most important coagulation markers for the risk assessment of COVID-19-related thrombosis, could be helpful in determining more suitable patients for anticoagulation therapy. In fact, D-dimer levels have been one of the major inclusion criteria in several previous randomized clinical trials investigating optimal anticoagulation therapy for COVID-19.14 However, to date, there limited data are available regarding the relationship between the occurrence of VTE and D-dimer levels in COVID-19 patients in Japan.18 Therefore, the aim of this study was to assess the association between D-dimer levels at admission and VTE events during hospitalization in patients with COVID-19, using the database of a large-scale, multicenter observational study for COVID-19.

Methods

Study Population

The CLOT-COVID study (Thrombosis and Anticoagulation Therapy in patients with COVID-19 in Japan Study; University Hospital Medical Information Network (UMIN) Clinical Trials Registry ID: UMIN45800) is a retrospective, physician-initiated, multicenter cohort study that enrolled consecutive hospitalized patients with COVID-19 across 16 centers in Japan from April 2021 to September 2021 (the fourth and fifth waves of COVID-19 infections in Japan). This study was conducted by dedicated members of the Taskforce of VTE and COVID-19 in Japan in collaboration with the Japanese Society of Phlebology and the Japan Pulmonary Embolism Study Group.13 Patients with a positive polymerase chain reaction test and a diagnosis of COVID-19 were consecutively enrolled from the hospital databases.

In all, 2,894 patients were enrolled into the CLOT-COVID study. After excluding 123 patients without D-dimer levels at admission, the present study population consisted of 2,771 (96%) patients who had D-dimer levels measured at admission. The study population was divided into 3 groups based on tertiles of D-dimer levels at admission: 1st tertile, D-dimer ≤0.5 μg/mL; 2nd tertile, D-dimer 0.51–1.09 μg/mL; 3rd tertile, D-dimer ≥1.1 μg/mL.

Ethics Approval and Consent to Participate

All procedures in this study were performed in accordance with the Declaration of Helsinki. The relevant review boards or ethics committees of all participating institutions approved the study protocol. Because clinical information obtained in routine clinical practice was used, the requirement for written informed consent from each patient was waived. This method is consistent with the Japanese Ministry of Health, Labor and Welfare’s guidelines for epidemiological studies.

Data Collection

Electronic reports were used to collect patient data and follow-up information. Data on patient characteristics, pharmacological thromboprophylaxis, and clinical outcomes were collected from hospital medical records or hospital databases according to prespecified definitions. The physicians at each institution were responsible for data entry into an electronic case report form. Furthermore, general office staff manually checked the data for omissions, inconsistencies, and values outside the expected range.

Definitions for Patient Characteristics

Hypertension was diagnosed if the peripheral blood pressure was 140/90 mmHg or higher or if the patient was taking medication for hypertension. Diabetes was diagnosed based on HbA1c levels (National Glycohemoglobin Standardization Program [NGSP], 6.5%) and was assumed if the patient was taking medication for diabetes. Heart disease was defined as any heart disease, including heart failure, angina pectoris, and previous myocardial infarction. Heart failure was diagnosed if a patient had a history of hospitalization for heart failure, symptoms due to heart failure (New York Heart Association [NYHA] functional class ≥2), or a left ventricular ejection fraction <40%. Respiratory diseases were defined as persistent lung diseases such as asthma, chronic obstructive pulmonary disease, and restrictive pulmonary disease. Patients with active cancer were defined as those undergoing cancer treatment, such as chemotherapy or radiotherapy, those scheduled for cancer surgery, those with metastasis to other organs, and/or those with end-stage cancer.19 A history of major bleeding was diagnosed if the patient had an ISTH history of major bleeding, consisting of a decrease in hemoglobin levels of at least 2 g/dL, the transfusion of at least 2 units of blood, and symptomatic bleeding in a critical site or organ.20 The severity of the COVID-19 was classified as mild, moderate, or severe; patients who did not require oxygen were defined as having mild COVID-19, those who required oxygen were defined as having moderate COVID-19, and those who required mechanical ventilation or extracorporeal membrane oxygenation were defined as having severe COVID-19.

The unfractionated heparin therapeutic dose was defined as unfractionated heparin administration targeting the therapeutic range with reference to the activated partial thromboplastin time (APTT). The unfractionated heparin prophylactic dose was defined as a fixed dose of unfractionated heparin and was not based on the APTT.

Clinical Outcomes

The primary outcome measure in the present study was VTE during the hospitalization. VTE was defined as pulmonary embolism (PE) and deep vein thrombosis (DVT) that was objectively confirmed by imaging studies (ultrasound, contrast-enhanced computed tomography, ventilation-perfusion lung scintigraphy, pulmonary angiography, contrast-enhanced venography) or autopsy. PE was classified into 5 categories according to the most central pulmonary artery site where the thrombi were located, namely the main trunk pulmonary artery, the left or right main pulmonary artery, the lobar artery, the segmental artery, or the subsegmental artery. Proximal DVT was defined as venous thrombosis occurring in the popliteal, femoral, or iliac veins. Distal DVT was defined as venous thrombosis located in the calf veins, including the peroneal, posterior tibial, anterior tibial, and soleus muscle veins below the knee.

Secondary outcome measures in the present study were major bleeding and all-cause death during hospitalization. Major bleeding was diagnosed as ISTH major bleeding, which consisted of a reduction in the hemoglobin level by
Table 1. Patient Characteristics, Pharmacological Thromboprophylaxis Management, and Imaging Examinations During Hospitalization

|                              | Total (n=2,771) | 1st (n=949; D-dimer ≤0.5μg/mL) | 2nd (n=894; D-dimer 0.51–1.09μg/mL) | 3rd (n=928; D-dimer ≥1.1μg/mL) | P value |
|------------------------------|----------------|--------------------------------|-----------------------------------|--------------------------------|---------|
| **Baseline characteristics** |                |                                |                                   |                                |         |
| Age (years)                  | 53.4±17.0      | 47.7±17.0                      | 52.5±15.3                         | 60.0±16.2                      | <0.001  |
| Men                          | 1,820 (65.7)   | 611 (64.4)                     | 592 (66.2)                        | 617 (66.5)                     | 0.58    |
| Body weight (kg)             | 69.7±17.7      | 68.6±17.1                      | 72.4±18.8                         | 68.7±17.7                      | <0.001  |
| Height (cm)                  | 165.1±10.1     | 165.3±10.5                     | 165.7±10.1                        | 164.4±9.6                      | 0.020   |
| Body mass index (kg/m²)      | 25.4±5.3       | 25.0±5.2                       | 26.2±5.6                          | 25.2±5.2                       | <0.001  |
| Body mass index >30kg/m²     | 449 (16.2)     | 139 (14.6)                     | 173 (19.4)                        | 137 (14.8)                     | 0.008   |
| D-dimer at admission (μg/mL) | 0.80 [0.50–1.30]| 0.50 [0.50–0.50]               | 0.77 [0.62–0.90]                  | 1.63 [1.30–2.87]               | <0.001  |
| **Comorbidities**            |                |                                |                                   |                                |         |
| Hypertension                 | 842 (30.4)     | 207 (21.8)                     | 295 (33.0)                        | 340 (36.6)                     | <0.001  |
| Diabetes                     | 582 (21.0)     | 125 (13.2)                     | 206 (23.0)                        | 251 (27.0)                     | <0.001  |
| Heart disease                | 244 (8.8)      | 60 (6.3)                       | 70 (7.8)                          | 114 (12.3)                     | <0.001  |
| Respiratory disease          | 289 (10.4)     | 88 (9.3)                       | 95 (10.6)                         | 106 (11.4)                     | 0.31    |
| Active cancer                | 55 (2.0)       | 7 (0.7)                        | 13 (1.5)                          | 35 (3.8)                       | <0.001  |
| History of major bleeding    | 25 (0.9)       | 4 (0.4)                        | 6 (0.7)                           | 15 (1.6)                       | 0.014   |
| History of VTE              | 13 (0.5)       | 4 (0.4)                        | 2 (0.2)                           | 7 (0.8)                        | 0.23    |
| **Severity of COVID-19 at admission** |                |                                |                                   |                                |         |
| Mild                         | 1,643 (59.3)   | 791 (83.4)                     | 540 (60.4)                        | 312 (33.6)                     |         |
| Moderate (needing oxygen)    | 913 (32.9)     | 148 (15.6)                     | 316 (35.3)                        | 449 (48.4)                     | <0.001  |
| Severe (mechanical ventilation) | 215 (7.8)     | 10 (1.1)                       | 38 (4.3)                          | 167 (18.0)                     |         |
| **Pharmacological thromboprophylaxis** |                |                                |                                   |                                |         |
| Anticoagulants               | 1,218 (44.0)   | 198 (20.9)                     | 384 (43.0)                        | 636 (68.5)                     | <0.001  |
| Unfractionated heparin of prophylactic dose | 680/1,218 (55.8) | 88/198 (44.4) | 229/384 (59.6) | 363/636 (57.1) |         |
| Unfractionated heparin of therapeutic dose | 154/1,218 (12.6) | 4/198 (2.0) | 28/384 (7.3) | 122/636 (19.2) |         |
| Low-molecular-weight heparin of prophylactic dose | 192/1,218 (15.8) | 58/198 (29.3) | 64/384 (16.7) | 70/636 (11.0) |         |
| Low-molecular-weight heparin of therapeutic dose | 0/1,218 (0.0) | 0/198 (0.0) | 0/384 (0.0) | 0/636 (0.0) |         |
| Direct oral anticoagulants   | 161/1,218 (13.2) | 39/198 (19.7) | 52/384 (13.5) | 70/636 (11.0) |         |
| Warfarin                     | 19/1,218 (1.6) | 7/198 (3.5) | 6/384 (1.6) | 6/636 (0.9) |         |
| **Imaging examinations during hospitalization** |                |                                |                                   |                                |         |
| Any imaging examination      | 145/2,771 (5.2) | 12/949 (1.3) | 23/894 (2.6) | 110/928 (11.9) | <0.001  |
| Ultrasound examination of the lower extremities | 38/2,771 (1.4) | 5/949 (0.5) | 5/894 (0.6) | 28/928 (3.0) | <0.001  |
| Contrast-enhanced CT examination | 120/2,771 (4.3) | 9/949 (0.9) | 20/894 (2.2) | 91/928 (9.8) | <0.001  |
| Reasons for performing contrast-enhanced CT |                |                                |                                   |                                |         |
| Suspicion of VTE            | 58/120 (48.3)  | 7/9 (77.8)                     | 5/20 (25.0)                       | 46/91 (50.5)                   |         |
| Other reasons               | 62/120 (51.7)  | 2/9 (22.2)                     | 15/20 (75.0)                      | 45/91 (49.5)                   |         |

Unless indicated otherwise, data are given as the mean±SD, median [interquartile range], or n (%). Unfractionated heparin of therapeutic dose was defined as administration of unfractionated heparin targeting the therapeutic range with a reference to the activated partial thromboplastin time (APTT). Unfractionated heparin of prophylactic dose was defined as administration of a fixed dose of unfractionated heparin without reference to the APTT. CT, computed tomography; VTE, venous thromboembolism.

at least 2 g/dL, transfusion of at least 2 units of blood, or symptomatic bleeding in a critical area or organ.20

Statistical Analysis
Categorical variables are presented as numbers and percentages. Continuous variables are presented as the mean±SD or the median and interquartile range (IQR) based on their distributions. Categorical variables were compared with the Chi-squared test when appropriate; otherwise, Fisher’s exact test was used. Continuous variables were compared using analysis of variance (ANOVA) or the Kruskal-Wallis test depending on their distributions. Clinical outcomes are presented as numbers of events and percentages. To adjust for clinically relevant variables, we constructed a multivariable logistic regression model to estimate the adjusted odds ratio (OR) and its 95% confidence interval (CI) of the 3rd tertile of D-dimer levels at admission, using the 1st tertile as the reference, for VTE events during hospitalization. Consistent with previous reports,10,21,22 and in consideration of clinical relevance, 4 risk-adjusting variables of patient characteristics at admission (age, sex, body mass index >30 kg/m², and severity of COVID-19 at admission)

Advance Publication
patients were divided into three groups (1st tertile, n=949; 2nd tertile, n=894; 3rd tertile, n=928), with median (IQR) D-dimer levels in the 1st, 2nd, and 3rd tertiles being 0.50 (0.50–0.50), 0.77 (0.62–0.90), and 1.63 (1.30–2.87) μg/mL, respectively. Patient characteristics differed in several aspects; the higher the D-dimer tertile, the older patients were, and the more prevalent hypertension, diabetes, heart disease, active cancer, and a history of major bleeding were (Table 1).

The higher the tertile group, the more severe the COVID-19 status at admission, with 83.4%, 60.4%, and 33.6% of patients were selected, in addition to pharmacological thromboprophylaxis. All statistical analyses were performed using SPSS version 23. All reported P values are 2-tailed, and P<0.05 was considered statistically significant.

### Results

#### Patient Characteristics at Admission

The median D-dimer level at admission in the entire cohort was 0.8 μg/mL (IR 0.5–1.3 μg/mL). Based on D-dimer levels, were selected, in addition to pharmacological thromboprophylaxis. All statistical analyses were performed using SPSS version 23. All reported P values are 2-tailed, and P<0.05 was considered statistically significant.

### Results

#### Patient Characteristics at Admission

The median D-dimer level at admission in the entire cohort was 0.8 μg/mL (IR 0.5–1.3 μg/mL). Based on D-dimer levels, were selected, in addition to pharmacological thromboprophylaxis. All statistical analyses were performed using SPSS version 23. All reported P values are 2-tailed, and P<0.05 was considered statistically significant.

### Results

#### Patient Characteristics at Admission

The median D-dimer level at admission in the entire cohort was 0.8 μg/mL (IR 0.5–1.3 μg/mL). Based on D-dimer levels,
patients in the 1st, 2nd, and 3rd tertiles, respectively, having mild COVID-19, 15.6%, 35.3%, and 48.4% of patients having moderate COVID-19, and 1.1%, 4.3%, and 18.0% of patients having severe COVID-19 (P<0.001).

**Pharmacological Thromboprophylaxis Management and Imaging Examinations During Hospitalization**

The higher the tertile group, the more frequent the pharmacological thromboprophylaxis (20.9%, 43.0%, and 68.5% of patients in the 1st, 2nd, and 3rd tertiles, respectively; P<0.001; Table 1). Patients in the 3rd tertile received anticoagulants, with prophylactic-dose heparin being the most common type of anticoagulation (57.1% 363/636), followed by therapeutic-dose heparin (19.2%; 122/636).

During hospitalization, contrast-enhanced CT and ultrasound examinations of the lower extremities were performed in 4.3% (120/2,771) and 1.4% (38/2,771) of patients in the entire study population, respectively (Table 1). Patients in the 3rd tertile more frequently underwent both contrast-enhanced CT and ultrasound examinations of the lower extremities (contrast-enhanced CT: 9.9%, 2.2%, and 9.8% of patients in the 1st, 2nd, and 3rd tertiles, respectively [P<0.001]; lower extremity ultrasound: 0.5%, 0.6%, and 3.0% of patients in the 1st, 2nd, and 3rd tertiles, respectively [P<0.001]; Figure 1).

**Clinical Outcomes**

The incidence of VTE during hospitalization was highest in the 3rd tertile (0.3%, 3.0%, and 3.6% in the 1st, 2nd, and 3rd tertiles, respectively; P<0.001; Table 2). Even after adjusting for confounders in the multivariable logistic regression model, the higher D-dimer levels in the 3rd tertile (≥1.1 μg/mL) were independently associated with a higher risk of VTE during hospitalization (adjusted OR 4.83; 95% CI 1.93–12.11; P<0.001; reference=1st tertile; Supplementary Table). The incidence rates of VTE among patients with imaging examinations (VTE-positive rates) were 25.0% in the 1st tertile, 13.1% in the 2nd tertile, and 30.0% in the 3rd tertile (Figure 2).

Similarly, the incidence of major bleeding and all-cause death during hospitalization was highest in the 3rd tertile (major bleeding: 0.6%, 1.3%, and 4.0% of patients in the 1st, 2nd, and 3rd tertiles, respectively [P<0.001]; all-cause death: 1.2%, 2.5%, and 12.5% of patients in the 1st, 2nd, and 3rd tertiles, respectively [P<0.001]; Table 2).

**Discussion**

The main findings of the present study are that: (1) patient characteristics differ in several aspects according to D-dimer levels at admission, including a more severe COVID-19 status of admission in the higher D-dimer tertiles with a higher prevalence of pharmacological thromboprophylaxis; and (2) patients in higher D-dimer tertiles more frequently underwent imaging examinations, and had a higher risk of the occurrence of VTE.

There are several points to keep in mind when interpreting the results of the present study. The incidence of VTE in the present study was lower than that in previous studies from outside Japan. However, it is unclear whether this is due to racial differences or the lower prevalence of imaging examinations. The possibility that the incidence of VTE events was underestimated due to a lower prevalence of imaging examinations needs to be considered. Conversely, the incidence of VTE may not necessarily be low, considering that many patients received pharmacological thromboprophylaxis.

The present study showed an association between the D-dimer level at admission and the severity of COVID-19 infection. Previous reports have shown an association between the severity of COVID-19 infection and the incidence of thrombotic events. Even for diseases other than COVID-19, the frequency of thrombosis increases in severely ill patients, including those with longer bed rest and complications of disseminated intravascular coagulation. However, in a previous report, the incidence of VTE was higher in patients admitted to the intensive care unit (ICU) with COVID-19 than in patients admitted to the ICU with other diseases or other viral infections. This suggests that COVID-19 itself may be associated with the higher risk of thrombosis, independent of the severity of a patient’s general condition, and that it is important to strive to prevent thrombosis.

It has been shown that D-dimer levels are associated with the development of thrombosis and the mortality of COVID-19 patients. For this reason, some guidance
recommends that coagulation markers, including D-dimer levels, should be evaluated first in the treatment of patients with COVID-19 and that low-molecular-weight heparin should be administered to all patients who require hospitalization unless there are contraindications. However, there are still insufficient data in Japan. The present study revealed the usefulness of D-dimer measurements in predicting the development of VTE in Japanese patients with COVID-19.

In the present study we divided D-dimer levels into tertiles, and approximated the cut-off values frequently used in clinical practice (0.5 and 1.0), which may be applicable to clinical practice. As in previous reports, the prevalence of imaging examinations including contrast-enhanced CT examinations and ultrasound examination of the lower extremities during hospitalization seemed to be low in the present study. The prevalence of imaging examinations was significantly higher for patients in the 3rd tertile than in the other tertiles, but was still only 11.9%. This may be due to the possibility that the respiratory symptoms of COVID-19 could have obscured the onset of PE, and so not enough imaging examinations were performed, or trying to avoid contact between COVID-19-positive patients and technicians, or problems in the hospital’s conduits. However, the VTE-positive rate was higher in the 3rd tertile group than in the other 2 groups. In addition, even after adjusting for confounders, the adjusted risk of VTE in the 3rd tertile group was significantly higher, with an adjusted OR of 4.83, which seemed to have a major impact on the occurrence of VTE. In this sense, D-dimer levels at admission could be a very important biomarker for stratifying the risk of VTE in Japanese patients with COVID-19. More aggressive imaging examinations may be reasonable for patients with high D-dimer levels at admission, especially when VTE is suspected.

Study Limitations
The present study has several limitations. First, the CLOT-COVID study was based on observational cohort data from 16 selected institutions in Japan, and the clinical decisions regarding the management and examination strategies were at the discretion of the attending physicians. In actual clinical practice for COVID-19, the rate of imaging tests was very low in terms of in-hospital conduits and contact avoidance. Therefore, the 145 cases examined by imaging studies represent a very limited cohort. To minimize the effect of this selection bias as much as possible, the D-dimer values of all 2,771 patients were assessed. Second, D-dimer testing methods and detection thresholds may differ among institutions. Third, these data were from centers approved the research protocol. The ethics committee of the primary institution was the Ethics Committee of Fukushima Daichi Hospital (Approval no. 2021-11-2).

Data Availability
The deidentified participant data will not be shared.

Conclusions
Higher D-dimer levels at admission were associated with a higher risk of VTE during hospitalization in Japanese patients with COVID-19, which could be helpful in determining patient-specific anticoagulation management strategies for COVID-19 in Japan.

Acknowledgments
The authors appreciate the support and collaboration of the Japanese Society of Phlebology and the Japanese Society of Pulmonary Embolism Research for the present study. The authors are indebted to Emi Kuroki, from the Japanese Society of Phlebology, for her technical support.

Sources of Funding
The CLOT-COVID study was supported, in part, by research funding from the Fujiiwa Memorial Foundation (Kyoto, Japan) and research funding from the Foundation Kyoto Health Care Society (Kyoto, Japan). The research funders had no role in the design or conduct of the study; the collection, management, analysis, or interpretation of the data; or in the preparation, review, or approval of the manuscript.

Disclosures
None of the authors have any relationships that are relevant to the contents of this paper.

IRB Information
The relevant review boards or ethics committees of all participating centers approved the research protocol. The ethics committee of the primary institution was the Ethics Committee of Fukushima Daichi Hospital (Approval no. 2021-11-2).

References
1. Lodigiani C, Iapichino G, Carenzo L, Cecconi M, Ferrazzi P, Sebastiani T, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res 2020; 191: 9 – 14.
2. Bilaloglu S, Aphiynanphongs Y, Jones S, Itrurrate E, Hochman J, Berger JS. Thrombosis in hospitalized patients with COVID-19 in a New York City health system. JAMA 2020; 324: 799 – 801.
3. Fraisse M, Logre E, Pajot O, Mentec H, Planteufel G, Contou D. Thrombotic and hemorrhagic events in critically ill COVID-19 patients: A French monocenter retrospective study. Crit Care 2020; 24: 275.
4. Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohama M, Delabranche X, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: A multicenter prospective cohort study. Intensive Care Med 2020; 46: 1089 – 1098.
5. Klok FA, Kruijp MJHA, van der Meer NJM, Arbous MS, Gommers DAMP, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020; 191: 145 – 147.
6. Klok FA, Kruijp MJHA, van der Meer NJM, Arbous MS, Gommers D, Kant KM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. Thromb Res 2020; 191: 148 – 150.
7. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost 2020; 18: 1421 – 1424.
8. Litjjes JF, Lexere M, Chochois C, Monsallier JM, Ramakers M, Auvray M, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost 2020; 18: 1743 – 1746.
9. Poissy J, Goutay J, Caplan M, Parmentier E, Dubarre T, Lassalle F, et al. Pulmonary embolism in patients with COVID-19: Awareness of an increased prevalence. Circulation 2020; 142: 184 – 186.
10. Zhang L, Feng X, Zhang D, Jiang C, Mei H, Wang J, et al. Deep vein thrombosis in hospitalized patients with COVID-19 in Wuhan, China: Prevalence, risk factors, and outcome. Circulation 2020; 142: 114 – 128.
11. Bikieli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and thrombotic or thromboembolic disease: Implications for prevention, antithrombotic therapy, and follow-up. JACC state-of-the-art review. J Am Coll Cardiol 2020; 75: 2950 – 2973.
12. Yamashita Y, Maruyama Y, Satokawa H, Nishimoto Y, Tsujino I, Sakashita H, et al. Incidence and clinical features of venous thromboembolism in hospitalized patients with coronavirus disease 2019 (COVID-19) in Japan. Circ J 2021; 85: 2208 – 2214.
13. Yamashita Y, Yamada N, Mo M. The primary prevention of
venous thromboembolism in patients with COVID-19 in Japan: Current status and future perspective. Ann Vasc Dis 2021; 14: 1–4.

14. Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost 2020; 18: 1023–1026.

15. Sholzberg M, Tang GH, Rahhal H, Al Hamzah M, Kreuziger LB, Ainele FN, et al. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. BMJ 2021; 375: n2400.

16. Spyropoulos AC, Goldin M, Giannis D, Diab W, Wang J, Khanjo S, et al. Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: The HEP-COVID randomized clinical trial. JAMA Intern Med 2021; 181: 1612–1620.

17. Lawler PR, Goligher EC, Berger JS, Neal MD, McVerry BJ, Nicolauc JC, et al. Therapeutic anticoagulation with heparin in noncritically ill patients with COVID-19. N Engl J Med 2021; 385: 790–802.

18. Oba S, Hosoya T, Amamiya M, Mtsumura T, Kawata D, Sasaki H, et al. Arterial and venous thrombosis complicated in COVID-19: A retrospective single center analysis in Japan. Front Cardiovasc Med 2021; 8: 767074.

19. Sakamoto J, Yamashita M, Morimoto T, Amano H, Takase T, Hiramori S, et al. Cancer-associated venous thromboembolism in the real world: From the COMMAND VTE Registry. Circ J 2019; 83: 2271–2281.

20. Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antithrombotic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 692–694.

21. Cohen SL, Gianos E, Barish MA, Chatterjee S, Kohn N, Lesser M, et al. Prevalence and predictors of venous thromboembolism or mortality in hospitalized COVID-19 patients. Thromb Haemost 2021; 121: 1043–1053.

22. Barbar S, Noventa F, Rossetto V, Ferrari A, Brandolin B, Perlati M, et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: The Padua Prediction Score. J Thromb Haemost 2010; 8: 2450–2457.

23. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382: 1708–1720.

24. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 2020; 395: 1054–1062.

25. Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: A prospective cohort study. Lancet 2020; 395: 1763–1770.

26. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020; 180: 934–943.

Supplementary Files

Please find supplementary file(s):
http://dx.doi.org/10.1253/circrep.CR-22-0022